Cancer cells thrive owing to different means of survival and proliferation. But despite growing understanding of the biology of cancer and the mechanism of tumorigenesis, complete knowledge of what causes cancer is still lacking. There are multiple hypotheses as to what drives cells to become malignant. One of them is the Warburg effect, which supports that an increase in glycolysis over oxidative respiration, even in the presence of oxygen, may be the cause of cancer. But this premise has not yet been confirmed. In 'Bench to Bedside', Michael Ohh peruses a recent study showing a common mutation in people with renal cell carcinoma and melanoma that may rekindle the debate as to whether a metabolic switch is a major driver in cancer and whether it has potential as a therapeutic target. Every so often, an 'old' drug seems to work for a condition that was not previously known. Two recent human studies show that aspirin can prevent colorectal cancer in people genetically predisposed to this disease after several years after treatment. In 'Bedside to Bench', Patrick Maxwell discusses the possible mechanisms of action of aspirin in decreasing the risk of developing colorectal cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients
Journal of Translational Medicine Open Access 13 February 2020
-
Maternal bile acid transporter deficiency promotes neonatal demise
Nature Communications Open Access 29 September 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Warburg, O. Science 123, 309–314 (1956).
Bertolotto, C. Nature 480, 94–98 (2011).
Garraway, L.A. et al. Nature 436, 117–122 (2005).
Okura, T. et al. J. Immunol. 157, 4277–4281 (1996).
Semenza, G.L. Science 318, 62–64 (2007).
Kaelin, W.G. Jr. & Ratcliffe, P.J. Mol. Cell 30, 393–402 (2008).
Cheng, J., Kang, X., Zhang, S. & Yeh, E.T. Cell 131, 584–595 (2007).
Baysal, B.E. et al. Science 287, 848–851 (2000).
Hao, H.X. et al. Science 325, 1139–1142 (2009).
Niemann, S. & Muller, U. Nat. Genet. 26, 268–270 (2000).
Tomlinson, I.P. et al. Nat. Genet. 30, 406–410 (2002).
Soucy, T.A. et al. Nature 458, 732–736 (2009).
Swords, R.T. et al. Blood 115, 3796–3800 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ohh, M. Tumor strengths and frailties: Cancer SUMmOns Otto's metabolism. Nat Med 18, 30–31 (2012). https://doi.org/10.1038/nm.2631
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2631
This article is cited by
-
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients
Journal of Translational Medicine (2020)
-
Maternal bile acid transporter deficiency promotes neonatal demise
Nature Communications (2015)